The serum matrix metalloproteinase-9 level is an independent predictor of recurrence after ablation of persistent atrial fibrillation.
OBJECTIVE
This study investigated whether the serum matrix metalloproteinase-9 level is an independent predictor of recurrence after catheter ablation for persistent atrial fibrillation.


METHODS
Fifty-eight consecutive patients with persistent atrial fibrillation were enrolled and underwent catheter ablation. The serum matrix metalloproteinase-9 level was detected before ablation and its relationship with recurrent arrhythmia was analyzed at the end of the follow-up.


RESULTS
After a mean follow-up of 12.1±7.2 months, 21 (36.2%) patients had a recurrence of their arrhythmia after catheter ablation. At baseline, the matrix metalloproteinase-9 level was higher in the patients with recurrence than in the non-recurrent group (305.77±88.90 vs 234.41±93.36 ng/ml, respectively, p=0.006). A multivariate analysis showed that the matrix metalloproteinase-9 level was an independent predictor of arrhythmia recurrence, as was a history of atrial fibrillation and the diameter of the left atrium.


CONCLUSIONS
The serum matrix metalloproteinase-9 level is an independent predictor of recurrent arrhythmia after catheter ablation in patients with persistent atrial fibrillation.
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.|Mayo Clinic, Department of Medicine, Division of Cardiovascular Diseases, Rochester, MN, USA.
Gang
G
Wu
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
Shun
S
Wang
Huazhong University of Science and Technology, Tongji Medical College, Tongji Hospital, Department of Geriatrics, Wuhan, Hubei, China.|Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Mian
M
Cheng
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
Bin
B
Peng
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
Jingjun
J
Liang
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
He
H
Huang
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
Xuejun
X
Jiang
Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Lizhi
L
Zhang
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
Bo
B
Yang
Mayo Clinic, Department of Medicine, Division of Cardiovascular Diseases, Rochester, MN, USA.
Yongmei
Y
Cha
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
Hong
H
Jiang
Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Department of Cardiology, Wuhan, Hubei, China.
Congxin
C
Huang
D000368:Aged; D001281:Atrial Fibrillation / Q000201:enzymology* / Q000503:physiopathology / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D004554:Electric Countershock / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D015999:Multivariate Analysis; D011184:Postoperative Period; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012008:Recurrence; D013997:Time Factors
D020780:Matrix Metalloproteinase 9